734例次感染性疾病会诊病例的临床药师干预效果与影响因素OA

AIM To evaluate the effectiveness of clinical pharmacist involvement in infectious disease consultations and to analyze factors influencing antimicrobial treatment outcomes,providing evidence for optimizing pharmaceutical services.METHODS A retrospective analysis was conducted on cases involving clinical pharmacists in anti-infective consultations at a hospital between January and December 2024.The acceptance rate of suggestions raised by clinical pharmacists in anti-infective consultation was used as the primary measure,and the clinical response rate was used as the study outcome.Patients were divided into an adoption group and a non-adoption group based on whether the consultation recommendations were adopted,and the clinical outcomes were compared between 2 groups.The multivariate logistic regression model was employed to analyze factors influencing clinical treatment outcomes(treatment efficacy and treatment inefficacy).RESULTS A total of 734 cases of infectious disease consultations were ultimately included.The purpose of clinical pharmacist consultation for anti-infective therapy primarily revolved around the selection of anti-infective drugs,accounting for 74.39％.A total of 635 anti-infective treatment consultation recommendations were adopted,with an adoption rate of 86.15％.The treatment efficacy rate in the adoption group demonstrated a statistically significant difference compared to the non-adoption group(86.68％vs 26.67％,P＜0.05).Multivariate logistic regression analysis identified that hypoalbuminemia and tumor diseases emerged as statistically validated risk factors for treatment inefficacy in anti-infective consultations involving clinical pharmacists,whereas single-discipline consultations,availability of microbiological testing,and adoption of clinical pharmacists' recommendations demonstrated significant protective effects correlated with therapeutic success(P＜0.05).CONCLUSION Clinical pharmacists' participation in infectious disease consultations plays a significant role in optimizing therapeutic protocols and improving patient clinical outcomes.